Philip Ashton-Rickardt

Philip Ashton-Rickardt

Hoofd Techniek/Wetenschap/O&O bij SIGILON THERAPEUTICS, INC.
62 jaar
Consumer Services
Health Technology

Profiel

Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.

Actieve functies van Philip Ashton-Rickardt

BedrijvenFunctieBegin
SIGILON THERAPEUTICS, INC. Hoofd Techniek/Wetenschap/O&O 14-06-2021

Eerdere bekende functies van Philip Ashton-Rickardt

BedrijvenFunctieEinde
Corporate Officer/Principal 01-06-2021
Oprichter 31-10-2019
Corporate Officer/Principal 01-06-2006
Corporate Officer/Principal -
Ervaring van Philip Ashton-Rickardt in detail bekijken

Opleiding van Philip Ashton-Rickardt

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

95

Eerstegraads connecties

7

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit7

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Philip Ashton-Rickardt
40 % korting: de beste tools voorbehouden aan abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU